Jason Gerberry is ranked #1975 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Jason Gerberry

BofA

Jason Gerberry

Q: How accurate are Jason Gerberry's stock ratings?

About 53% of Jason's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, measured by 13Foresight from historical prices.

Bank of America Securities

Wall Street Analyst

★★★☆☆

#1975

on 13Foresight · ranked by our own returns

53%

Success Rate

-0.8%

Average Return

96 of 180 calls profitable · -139.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 53% of Jason Gerberry's ratings turned a profit when each position was held for 2 year — averaging -0.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

191 Buy 49 Hold 30 Sell

Jason's Stock Coverage 59 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
LENZ LENZ Therapeutics	Oct 30, 2026	HOLD	Buy +470.0% avg upside 17 analysts	$4.00 31.05% Upside	+35.4%	·
MRK Merck & Company	Oct 30, 2026	BUY	Strong Buy -3.5% avg upside 44 analysts	$165.00 10.28% Upside	-1.2%	·
LLY Eli Lilly & Co	Oct 29, 2026	BUY	Strong Buy -16.7% avg upside 50 analysts	$1497.00 5.53% Upside	+3.9%	·
BMY Bristol-Myers Squibb	Oct 29, 2026	BUY	Buy -2.2% avg upside 42 analysts	$67.00 7.31% Upside	+1.4%	·
ABBV AbbVie	Oct 22, 2026	BUY	Strong Buy -14.5% avg upside 47 analysts	$305.00 3.48% Upside	+3.5%	·
LQDA Liquidia Technologies	Oct 14, 2026	HOLD	Strong Buy +0.7% avg upside 15 analysts	$42.00 6.75% Downside	+69.2%	·
JNJ Johnson & Johnson	Oct 14, 2026	HOLD	Strong Buy -9.1% avg upside 40 analysts	$275.00 0.68% Upside	+11.7%	·
HRMY Harmony Biosciences Holdings	Oct 12, 2026	SELL	Strong Buy +27.3% avg upside 14 analysts	$30.00 22.68% Downside	+11.7%	·
XENE Xenon	Oct 12, 2026	BUY	Strong Buy +53.0% avg upside 28 analysts	$77.00 105.85% Upside	+13.0%	·
ARWR Arrowhead Pharmaceuticals	Oct 12, 2026	BUY	Strong Buy +26.6% avg upside 29 analysts	$100.00 66.90% Upside	-18.7%	·
VTRS Viatris	Oct 12, 2026	SELL	Buy +25.5% avg upside 22 analysts	$16.00 15.85% Downside	-18.7%	·
APMD Apnimed, Inc.	Oct 12, 2026	BUY	Strong Buy +206.9% avg upside 4 analysts	$41.00 150.02% Upside	-9.2%	·
GUTS Fractyl Health, Inc.	Oct 12, 2026	BUY	Strong Buy +1326.9% avg upside 7 analysts	$24.00 2357.77% Upside	-79.6%	·
MLYS Mineralys Therapeutics, Inc.	Oct 12, 2026	BUY	Strong Buy +150.9% avg upside 12 analysts	$49.00 169.59% Upside	-31.0%	·
OCS Oculis Holding	Oct 12, 2026	BUY	Strong Buy +367.7% avg upside 11 analysts	$32.00 287.45% Upside	-3.0%	·
ALVO Alvotech	Oct 12, 2026	BUY	Strong Buy +87.4% avg upside 7 analysts	$7.00 50.47% Upside	-23.4%	·
TARS Tarsus Pharmaceuticals	Oct 12, 2026	BUY	Strong Buy +9.9% avg upside 17 analysts	$84.00 12.29% Upside	+7.9%	·
BMRN BioMarin Pharmaceutical	Oct 09, 2026	BUY	Strong Buy +63.6% avg upside 52 analysts	$86.00 46.99% Upside	+4.4%	·
IL:TEVA Teva	Oct 09, 2026	BUY	Strong Buy +18.1% avg upside 8 analysts	$13521.63 5.67% Upside	+7.5%	·
RPRX Royalty Pharma	Oct 09, 2026	BUY	Strong Buy -12.2% avg upside 15 analysts	$63.00 6.29% Downside	+21.8%	·
AXSM Axsome Therapeutics	Oct 09, 2026	BUY	Strong Buy +63.9% avg upside 30 analysts	$276.00 91.17% Upside	-15.8%	·
UTHR United Therapeutics	Oct 09, 2026	HOLD	Buy -22.7% avg upside 27 analysts	$559.00 6.56% Downside	+7.6%	·
PFE Pfizer	Oct 09, 2026	HOLD	Buy +9.2% avg upside 46 analysts	$29.00 4.94% Downside	+5.2%	·
JAZZ Jazz Pharmaceuticals	Oct 09, 2026	BUY	Strong Buy +16.2% avg upside 36 analysts	$313.00 44.87% Upside	+10.6%	·
IONS Ionis Pharmaceuticals	Oct 09, 2026	BUY	Strong Buy +74.1% avg upside 44 analysts	$91.00 109.09% Upside	-31.5%	·
EXEL Exelixis	Oct 09, 2026	SELL	Buy -34.0% avg upside 34 analysts	$41.00 40.96% Downside	-15.3%	·
ALKS Alkermes	Oct 09, 2026	SELL	Buy -3.4% avg upside 34 analysts	$38.00 16.14% Downside	-14.0%	·
PCVX Vaxcyte	Oct 05, 2026	BUY	Strong Buy +77.8% avg upside 15 analysts	$146.00 135.34% Upside	-14.2%	·
AMLX Amylyx Pharmaceuticals Inc	Aug 18, 2026	BUY	Strong Buy +31.6% avg upside 14 analysts	$39.00 35.21% Upside	-13.7%	·
AMPH Amphastar Pharmaceuticals	Aug 07, 2026	SELL	Hold -3.5% avg upside 11 analysts	$20.00 27.76% Downside	-38.9%	·
IMVT Immunovant	May 21, 2026	BUY	Strong Buy +38.4% avg upside 25 analysts	$43.00 47.40% Upside	+0.8%	·
TSE:BHC Bausch Health Companies	Feb 18, 2026	SELL	Buy +386.9% avg upside 30 analysts	$6.99 39.12% Downside	-35.8%	·
OGN Organon	Feb 13, 2026	SELL	Sell +7.4% avg upside 9 analysts	—	-89.4%	·
PROK ProKidney	Jan 12, 2026	SELL	Buy +393.1% avg upside 12 analysts	$1.00 22.76% Downside	+54.9%	·
BHVN Biohaven Ltd.	Nov 10, 2025	HOLD	Buy +51.3% avg upside 25 analysts	$10.00 35.11% Downside	+77.4%	·
NL:LKFT Lakefront Biotherapeutics NV	Nov 07, 2025	SELL	Sell +75.8% avg upside 17 analysts	—	-7.7%	·
RLAY Relay Therapeutics	Nov 06, 2025	BUY	Strong Buy +22.4% avg upside 22 analysts	$15.00 18.21% Downside	+177.0%	·
LKFT Lakefront Biotherapeutics	Nov 06, 2025	SELL	Buy +217.3% avg upside 25 analysts	$28.00 13.18% Downside	-7.2%	·
LYRA Lyra Therapeutics	May 23, 2024	HOLD	Hold +12005.3% avg upside 7 analysts	—	·	·
CHRS Coherus Biosciences	Oct 30, 2023	HOLD	Buy +1336.6% avg upside 19 analysts	—	-43.5%	·
ALLO Allogene Therapeutics	Sep 28, 2023	HOLD	Strong Buy +1186.8% avg upside 28 analysts	—	-63.3%	·
TVRD Tvardi Therapeutics	Aug 09, 2023	SELL	Buy +2090.0% avg upside 24 analysts	$3.50 341.40% Upside	·	·
KYNB Kyntra Bio	Aug 08, 2023	SELL	Buy +615.8% avg upside 17 analysts	$2.00 56.28% Downside	+75.8%	·
BYSI Beyondspring	Jan 05, 2023	SELL	Buy +1152.3% avg upside 8 analysts	$1.00 55.32% Upside	+11.9%	·
VRCA Verrica Pharmaceuticals	Jul 15, 2020	HOLD	Strong Buy +411.2% avg upside 9 analysts	$10.00 198.49% Upside	-59.5%	·
YARW Yarrow Bioscience	Mar 11, 2020	BUY	Strong Buy +38.5% avg upside 9 analysts	$32.00 60.81% Upside	·	·
ALNY Alnylam Pharma	Nov 13, 2019	BUY	Strong Buy +76.3% avg upside 53 analysts	$110.00 33.36% Downside	+88.6%	·
NBRVF Nabriva Therapeutics	Aug 20, 2019	BUY	Buy +13374900.0% avg upside 9 analysts	$6.00 5999900.09% Upside	·	·
DE:MRK Merck KGaA	Jun 28, 2019	SELL	Buy -7.2% avg upside 34 analysts	—	-75.1%	·
SPRO Spero Therapeutics	Oct 16, 2018	SELL	Buy +1102.8% avg upside 13 analysts	$9.00 749.09% Upside	-52.8%	·
ARDX Ardelyx	Nov 20, 2016	BUY	Strong Buy +324.3% avg upside 21 analysts	$18.00 494.00% Upside	-81.6%	·
HRTX Heron Therapeutics	Nov 15, 2016	BUY	Strong Buy +10208.0% avg upside 21 analysts	$34.00 12143.42% Upside	·	·
PCRX Pacira Pharmaceuticals	Nov 02, 2016	HOLD	Hold +11.8% avg upside 23 analysts	$37.00 1.62% Upside	+50.9%	·
PRGO Perrigo Company	Aug 10, 2016	HOLD	Buy +333.3% avg upside 20 analysts	$81.00 413.24% Upside	-17.4%	·
AMRX Amneal Pharmaceuticals	Aug 09, 2016	HOLD	Strong Buy -10.1% avg upside 19 analysts	$24.00 11.55% Upside	·	·
NVO Novo Nordisk	Aug 08, 2016	HOLD	Hold +188.3% avg upside 26 analysts	—	+5.4%	·
IRWD Ironwood Pharma	Aug 05, 2016	HOLD	Buy +239.4% avg upside 23 analysts	$14.00 300.04% Upside	+43.4%	·
NBIX Neurocrine	Jul 13, 2016	BUY	Strong Buy +27.3% avg upside 37 analysts	$70.00 52.12% Downside	+121.3%	·
CARM Carisma Therapeutics	Jan 19, 2016	HOLD	Buy +584900.0% avg upside 11 analysts	—	·	·

🔒 54 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jason Gerberry — Frequently Asked Questions

How accurate are Jason Gerberry's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Jason's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, or -137.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Jason ranked on 13Foresight?

Jason Gerberry is currently ranked #1975 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jason cover?

Jason most recently has ratings on LENZ, MRK, LLY, BMY, ABBV, LQDA, JNJ, HRMY, XENE, ARWR, VTRS, APMD and 47 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Jason Gerberry

Rating Distribution

Welcome to 13Foresight!